Positioning of glucocorticosteroids in asthma and allergic rhinitis guidelines (versus other therapies)

Immunology and Allergy Clinics of North America

Volumn 25, Issue 3, 2005, Pages 597-612

  Joos, Guy F ^a   Brusselle, Guy G ^a   Van Hoecke, Helen ^a   Van Cauwenberge, Paul ^a   Bousquet, Jean ^b   Pauwels, Romain A ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LIPOXYGENASE INHIBITOR; METHYLPREDNISOLONE; MOMETASONE FUROATE; MONTELUKAST; NEDOCROMIL SODIUM; OXITROPIUM BROMIDE; PIRBUTEROL; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; ZILEUTON;

ALLERGIC RHINITIS; ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; COMPLIANCE (PHYSICAL); DISEASE SEVERITY; DRUG SAFETY; ENVIRONMENTAL FACTOR; HUMAN; IMMUNOTHERAPY; LUNG FUNCTION; MONOTHERAPY; PATIENT EDUCATION; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ASTHMA; GLUCOCORTICOIDS; HUMANS; PRACTICE GUIDELINES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 23044438303     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2005.06.001     Document Type: Review

References (70)

1. J. Bousquet, P. Van Cauwenberge, and N. Khaltaev Allergic Rhinitis and its Impact on Asthma (ARIA) Allergy 57 2002 841 855
2. Global Initiative for Asthma (GINA) Global Strategy for asthma management and prevention 1995 National Heart, Lung and Blood Institute, National Institutes of Health Bethesda (MD)
3. Global Initiative for Asthma (GINA) 2002. Global strategy for asthma management and prevention 2002 National Institutes of Health, National Heart and Blood Institute Bethesda (MD)
4. K.F. Rabe, M. Adachi, and C.K. Lai Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys J Allergy Clin Immunol 114 2004 40 47
5. C.K. Lai, T.S. De Guia, and Y.Y. Kim Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study J Allergy Clin Immunol 111 2003 263 268
6. J. Bousquet, P. Van Cauwenberge, and N. Khaltaev Allergic rhinitis and its impact on asthma J Allergy Clin Immunol 108 2001 S147 S334
7. G.K. Scadding, D.H. Richards, and M.J. Price Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis Clin Otolaryngol Allied Sci 25 2000 551 557
8. F.E. Simons Learning impairment and allergic rhinitis Allergy Asthma Proc 17 1996 185 189
9. M.S. Dykewicz, S. Fineman, and D.P. Skoner Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology Ann Allergy Asthma Immunol 81 1998 478 518
10. International Rhinitis Management Working Group International consensus report on the diagnosis and management of rhinitis Allergy 49 1994 5 34
11. P. Van Cauwenberge, C. Bachert, and G. Passalacqua Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology Allergy 55 2000 116 134
12. J. Bousquet, P. Van Cauwenberge, and C. Bachert Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA) Allergy 58 2003 192 197
13. J. Bousquet, V.J. Lund, and P. Van Cauwenberge Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial Allergy 58 2003 733 741
14. G. Feder, M. Eccles, and R. Grol Clinical guidelines: using clinical guidelines BMJ 318 1999 728 730
15. C. Gregory, M. Cifaldi, and L.A. Tanner Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population Am J Manag Care 5 1999 485 496
16. R. Djukanovic, J.W. Wilson, and K.M. Britten Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma Am Rev Respir Dis 145 1992 669 674
17. L.A. Laitinen, A. Laitinen, and T. Haahtela A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial J Allergy Clin Immunol 90 1992 32 42
18. J.W. Wilson, R. Djukanovic, and P.H. Howarth Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma Am J Respir Crit Care Med 149 1994 86 90
19. The Childhood Asthma Management Program Research Group Long term effects of budesonide or nedocromil in children with asthma N Engl J Med 343 2000 1054 1063
20. P.J. Barnes, S. Pedersen, and W.W. Busse Efficacy and safety of inhaled corticosteroids: new developments Am J Respir Crit Care Med 157 1998 S1 S53
21. R.A. Pauwels, S. Pedersen, and W.W. Busse Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial Lancet 361 2003 1071 1076
22. C.E. Reed, K.P. Offord, and H.S. Nelson Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group J Allergy Clin Immunol 101 1998 14 23
23. R. Dahl, B.B. Larsen, and P. Venge Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms Respir Med 96 2002 432 438
24. P.J. Barnes Theophylline: new perspectives for an old drug Am J Respir Crit Care Med 167 2003 813 818
25. J.M. Drazen, E. Israel, and P.M. O'Byrne Treatment of asthma with drugs modifying the leukotriene pathway N Engl J Med 340 1999 197 206
26. B.J. Lipworth Leukotriene-receptor antagonists Lancet 353 1999 57 62
27. E.R. Bleecker, M.J. Welch, and S.F. Weinstein Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma J Allergy Clin Immunol 105 2000 1123 1129
28. N.C. Barnes, and C.J. Miller Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials Thorax 55 2000 478 483
29. F.M. Ducharme Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence BMJ 326 2003 621 623
30. S.E. Dahlen, K. Malmstrom, and E. Nizankowska Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial Am J Respir Crit Care Med 165 2002 9 14
31. S.J. Szefler, and H.S. Nelson Alternative agents for anti-inflammatory treatment of asthma J Allergy Clin Immunol 102 1998 S23 S35
32. H.A. Boushey, C.A. Sorkness, and T.S. King Daily versus as-needed corticosteroids for mild persistent asthma N Engl J Med 352 2005 1519 1528
33. J.K. Sont, L.N. Willems, and E.H. Bel Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group Am J Respir Crit Care Med 159 1999 1043 1051
34. R.H. Green, C.E. Brightling, and S. McKenna Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial Lancet 360 2002 1715 1721
35. S. Shrewsbury, S. Pyke, and M. Britton Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) BMJ 320 2000 1368 1373
36. A.P. Greening, P.W. Ind, and M. Northfield Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group Lancet 344 1994 219 224
37. A. Woolcock, B. Lundback, and N. Ringdal Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids Am J Respir Crit Care Med 153 1996 1481 1488
38. R.A. Pauwels, C.G. Lofdahl, and D.S. Postma Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group N Engl J Med 337 1997 1405 1411
39. A.E. Tattersfield, D.S. Postma, and P.J. Barnes Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group Am J Respir Crit Care Med 160 1999 594 599
40. M. Masoli, M. Weatherall, and S. Holt Clinical dose-response relationship of fluticasone propionate in adults with asthma Thorax 59 2004 16 20
41. E.D. Bateman, H.A. Boushey, and J. Bousquet Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 170 2004 836 844
42. P.M. O'Byrne, P.J. Barnes, and R. Rodriguez-Roisin Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial Am J Respir Crit Care Med 164 2001 1392 1397
43. W.J. Calhoun, K.L. Hinton, and J.J. Kratzenberg The effect of salmeterol on markers of airway inflammation following segmental allergen challenge Am J Respir Crit Care Med 163 2001 881 886
44. A. Wallin, M. Sue-Chu, and L. Bjermer Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma J Allergy Clin Immunol 112 2003 72 78
45. S.C. Lazarus, H.A. Boushey, and J.V. Fahy Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial JAMA 285 2001 2583 2593
46. R.F. Lemanske Jr, C.A. Sorkness, and E.A. Mauger Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial JAMA 285 2001 2594 2603
47. O. Zetterstrom, R. Buhl, and H. Mellem Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone Eur Respir J 18 2001 262 268
48. H.S. Nelson, K.R. Chapman, and S.D. Pyke Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers J Allergy Clin Immunol 112 2003 29 36
49. M. Kavuru, J. Melamed, and G. Gross Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial J Allergy Clin Immunol 105 2000 1108 1116
50. M. Aubier, W.R. Pieters, and N.J. Schlosser Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma Respir Med 93 1999 876 884
51. G. Shapiro, W. Lumry, and J. Wolfe Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma Am J Respir Crit Care Med 161 2000 527 534
52. S.W. Stoloff, D.A. Stempel, and J. Meyer Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies J Allergy Clin Immunol 113 2004 245 251
53. D.J. Evans, D.A. Taylor, and O. Zetterstrom A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma N Engl J Med 337 1997 1412 1418
54. D. Ukena, U. Harnest, and R. Sakalauskas Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma Eur Respir J 10 1997 2754 2760
55. S. Lim, A. Jatakanon, and D. Gordon Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice Thorax 55 2000 837 841
56. B. Davies, G. Brooks, and M. Devoy The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies Respir Med 92 1998 256 263
57. A.J. Wilson, P.G. Gibson, and J. Coughlan Long acting beta-agonists versus theophylline for maintenance treatment of asthma Cochrane Database Syst Rev 2000 CD001281
58. L. Shah, A.J. Wilson, and P.G. Gibson Long acting beta-agonists versus theophylline for maintenance treatment of asthma Cochrane Database Syst Rev 2003 CD001281
59. M. Laviolette, K. Malmstrom, and S. Lu Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group Am J Respir Crit Care Med 160 1999 1862 1868
60. M.J. Vaquerizo, P. Casan, and J. Castillo Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma Thorax 58 2003 204 210
61. D.B. Price, D. Hernandez, and P. Magyar Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma Thorax 58 2003 211 216
62. R.A. Nathan, J.A. Bernstein, and L. Bielory Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction J Allergy Clin Immunol 102 1998 935 942
63. F.M. Ducharme Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence BMJ 324 2002 1545 1548
64. W. Busse, H. Nelson, and J. Wolfe Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma J Allergy Clin Immunol 103 1999 1075 1080
65. L. Bjermer, H. Bisgaard, and J. Bousquet Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial BMJ 327 2003 891 895
66. M. Soler, J. Matz, and R. Townley The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Eur Respir J 18 2001 254 261
67. B.Q. Lanier, J. Corren, and W. Lumry Omalizumab is effective in the long-term control of severe allergic asthma Ann Allergy Asthma Immunol 91 2003 154 159
68. W. Busse, J. Corren, and B.Q. Lanier Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
69. S.T. Holgate, A.G. Chuchalin, and J. Hebert Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
70. J.G. Ayres, B. Higgins, and E.R. Chilvers Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma Allergy 59 2004 701 708